Japan's Hitachi High-Tech and Swiss firm Roche have extended their partnership, committing to at least 10 years of additional collaboration. Bringing together the companies' expertise and track record in diagnostics innovation, engineering and manufacturing, the renewed contract further strengthens the two companies' long lasting partnership.

Together, the companies have delivered significant innovations that paved the way for industry-leading in-vitro diagnostic solutions. From revolutionising the clinical lab with the world's first multi-channel analyser, to the automation of immunology, the collaboration has led to groundbreaking innovations that have enabled labs and healthcare systems to overcome delivery challenges and get patients the care they need.

Later this year, Roche and Hitachi High-Tech plan to introduce new innovations including the new analytical units cobas c 703 and cobas ISE neo for cobas pro integrated solutions, to increase potential testing capacity for labs and provide accurate and timely diagnosis for millions of patients around the world.

By the end of the year, the introduction of the new cobas Mass Spec solution will mark another exciting milestone by integrating fully-automated mass spectrometry into the routine lab. This will make this gold standard technology available to more people around the world across various clinical applications.

"Hitachi High-Tech and Roche have worked together to expand in the field of in-vitro diagnostics by boldly pursuing innovations. The renewal of this agreement demonstrates both companies' commitment to the future of the global diagnostics market. We look forward to continuing to work together to further expand the utility of in-vitro diagnostics in healthcare," said Taku Sakazume, Executive Officer, Head of Diagnostic System Business, Hitachi High-Tech Corporation.